Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
Provider: Pechala's Reports
Provider: Pechala's Reports
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Atossa Genetics Inc announces pricing of public offering of common stock and warrants

Friday, 24 Jan 2014 08:30am EST 

Atossa Genetics Inc:Says it has priced a public offering of approximately 5.8 million units at a price to the public of $2.40 per unit.Says the company has received commitments and indications for approximately $14.0 million in gross proceeds. The sale of the units is expected to close on or about Jan. 29, subject to the satisfaction of customary closing conditions.Says each unit consists of one share of common stock and one warrant to purchase 0.20 of a share of common stock.Says Atossa intends to use the net proceeds of this offering for general corporate purposes, which include, but are not limited to, funding the ongoing and future development and re-launch of the ForeCYTE Breast Aspirator.Says when it receives regulatory clearance, funding the development of the other products in the pipeline including the FullCYTE Breast Health Test, NextCYTE Breast Cancer Test, ArgusCYTE Breast Health Test, the planned intra-ductal treatment program.Says and for general and administrative expenses.Says Dawson James Securities, Inc. is acting as the sole book-running manager for the offering. 

Company Quote

27 May 2015